Clinical Research Directory

Inclusion Criteria: * Age \> 18 * Karnofsky Performance Status (KPS) of \> 70 * Presence of at least one metastatic lesion that is to be removed surgically as part of standard care (e.g. diagnosis or diagnostic testing, mono- or oligometastatic disease, alleviation of symptoms etc) * • Diagnosis of metastatic melanoma with at least one lesion that is amenable for surgical resection per standard of care (e.g. diagnosis or diagnostic testing, mono- or oligometastatic disease, alleviation of symptoms etc) * Considered appropriate for standard anti-PD1 antibody monotherapy by managing physician * Given written informed consent to participate in the study Exclusion Criteria: * Known to have active hepatitis B or C or HIV (need not be screened) * KPS of \< 70; see Appendix A * Known underlying cardiac disease associated with myocardial dysfunction that requires active medical treatment, or unstable angina related to atherosclerotic cardiovascular disease, or under treatment for arterial or venous peripheral vascular disease * Diagnosis of any other invasive cancer or other disease process which is considered to be life-threatening within the next five years, and/or taking anti-cancer therapy for cancer other than melanoma * Active infection that could be eminently life-threatening or other active medical condition that could be eminently life-threatening, including active blood clotting or bleeding diathesis. * Known autoimmune disease, immunodeficiency, or disease process that involves the chronic or intermittent use of immunosuppressive therapy * Uncontrolled brain or spinal cord metastases or active leptomingeal metastatic disease. * Received another investigational drug within 28 days of the first dose or are planning to receive another investigational drug while receiving this investigational treatment * Known hypersensitivity to GM-CSF * Pregnancy